PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Clin Pathol. 1999 April; 52(4): 249–253.
PMCID: PMC501326

Human papillomavirus and the development of non-melanoma skin cancer.

Abstract

Human papillomaviruses (HPV) are increasingly recognised as important human carcinogens. The best established association with human malignancy is that of high-risk mucosal HPV types and anogenital cancer. HPV-induced transformation of anogenital epithelia has been the subject of intense research which has identified the cellular tumour suppressor gene products, p53 and pRB, as important targets for the viral oncoproteins E6 and E7 respectively. Certain HPV types are also strongly associated with the development of non-melanoma skin cancer in the inherited disorder epidermodysplasia verruciformis (EV). However, in contrast with anogenital malignancy the oncogenic mechanisms of EV-HPV types remain uncertain, and there appears to be a crucial additional requirement for ultraviolet radiation. Cutaneous HPV types in the general population are predominantly associated with benign viral warts, but a role in non-melanoma skin cancer has recently been postulated. Polymerase chain reaction based HPV detection techniques have shown a high prevalence of HPV DNA, particularly in skin cancers from immunosuppressed patients and to a lesser extent in malignancies from otherwise immunocompetent individuals. No particular HPV type has yet emerged as predominant, and the role of HPV in cutaneous malignancy is unclear at present. It remains to be established whether HPV plays an active or purely a passenger role in the evolution of non-melanoma skin cancer.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (956K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ko CB, Walton S, Keczkes K, Bury HP, Nicholson C. The emerging epidemic of skin cancer. Br J Dermatol. 1994 Mar;130(3):269–272. [PubMed]
  • Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct;131(4):455–464. [PubMed]
  • Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216–4220. [PubMed]
  • Rees J. Genetic alterations in non-melanoma skin cancer. J Invest Dermatol. 1994 Dec;103(6):747–750. [PubMed]
  • zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996 Oct 9;1288(2):F55–F78. [PubMed]
  • Majewski S, Jabłońska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol. 1995 Nov;131(11):1312–1318. [PubMed]
  • Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H, de Villiers EM. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res. 1994 Sep 1;54(17):4610–4613. [PubMed]
  • Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C, Hamm H, Goos M, Haustein UF, Jung EG, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst. 1996 Jun 19;88(12):802–811. [PubMed]
  • de Jong-Tieben LM, Berkhout RJ, Smits HL, Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, ter Schegget J. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol. 1995 Sep;105(3):367–371. [PubMed]
  • de Villiers EM, Lavergne D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer. 1997 Nov 4;73(3):356–361. [PubMed]
  • de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol. 1994;186:1–12. [PubMed]
  • Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol. 1995 May;69(5):3074–3083. [PMC free article] [PubMed]
  • Orth G. Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. Ciba Found Symp. 1986;120:157–174. [PubMed]
  • Cooper KD, Androphy EJ, Lowy D, Katz SI. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol. 1990 Jun;94(6):769–776. [PubMed]
  • Woodworth CD, Doniger J, DiPaolo JA. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol. 1989 Jan;63(1):159–164. [PMC free article] [PubMed]
  • Iftner T, Bierfelder S, Csapo Z, Pfister H. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol. 1988 Oct;62(10):3655–3661. [PMC free article] [PubMed]
  • Kiyono T, Nagashima K, Ishibashi M. The primary structure of major viral RNA in a rat cell line transfected with type 47 human papillomavirus DNA and the transforming activity of its cDNA and E6 gene. Virology. 1989 Dec;173(2):551–565. [PubMed]
  • Steger G, Pfister H. In vitro expressed HPV 8 E6 protein does not bind p53. Arch Virol. 1992;125(1-4):355–360. [PubMed]
  • May M, Grassmann K, Pfister H, Fuchs PG. Transcriptional silencer of the human papillomavirus type 8 late promoter interacts alternatively with the viral trans activator E2 or with a cellular factor. J Virol. 1994 Jun;68(6):3612–3619. [PMC free article] [PubMed]
  • Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frödin L, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995 Jan 17;60(2):183–189. [PubMed]
  • Sheil AG, Flavel S, Disney AP, Mathew TH. Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc. 1985 Apr;17(2):1685–1688. [PubMed]
  • Hardie IR, Strong RW, Hartley LC, Woodruff PW, Clunie GJ. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery. 1980 Feb;87(2):177–183. [PubMed]
  • Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990 Mar;49(3):506–509. [PubMed]
  • London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995 Aug 12;346(8972):403–406. [PubMed]
  • Boyle J, MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet. 1984 Mar 31;1(8379):702–705. [PubMed]
  • Blessing K, McLaren KM, Benton EC, Barr BB, Bunney MH, Smith IW, Beveridge GW. Histopathology of skin lesions in renal allograft recipients--an assessment of viral features and dysplasia. Histopathology. 1989 Feb;14(2):129–139. [PubMed]
  • Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998 May 21;393(6682):229–234. [PubMed]
  • Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol. 1993 Dec;29(6):1013–1022. [PubMed]
  • Young AR. Photocarcinogenicity of psoralens used in PUVA treatment: present status in mouse and man. J Photochem Photobiol B. 1990 Jun;6(1-2):237–247. [PubMed]
  • Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol. 1997 Aug;109(2):238–243. [PubMed]
  • Ullrich SE. Systemic immunosuppression of cell-mediated immune reactions by a monofunctional psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed. 1991 Jun;8(3):116–122. [PubMed]
  • Kripke ML, Morison WL, Parrish JA. Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA). J Invest Dermatol. 1983 Aug;81(2):87–92. [PubMed]
  • Harwood CA, Spink PJ, Surentheran T, Leigh IM, Hawke JL, Proby CM, Breuer J, McGregor JM. Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol. 1998 Jul;111(1):123–127. [PubMed]
  • Weinstock MA, Coulter S, Bates J, Bogaars HA, Larson PL, Burmer GC. Human papillomavirus and widespread cutaneous carcinoma after PUVA photochemotherapy. Arch Dermatol. 1995 Jun;131(6):701–704. [PubMed]
  • Rübben A, Baron JM, Grussendorf-Conen EI. Demonstration of human papillomavirus type 16-related DNA and absence of detectable p53 gene mutations in widespread cutaneous squamous cell carcinomas after oral psoralen with UV-A treatment. Arch Dermatol. 1996 Oct;132(10):1257–1259. [PubMed]
  • Bayle-Lebey P, Labadie F, Basset-Seguin N, Bazex J. Carcinomes cutanés et papillomavirus 5. Révélation lors d'une photochimiothérapie UVA prolongée. Ann Dermatol Venereol. 1994;121(6-7):496–498. [PubMed]
  • Hirt L, Hirsch-Behnam A, de Villiers EM. Nucleotide sequence of human papillomavirus (HPV) type 41: an unusual HPV type without a typical E2 binding site consensus sequence. Virus Res. 1991 Mar;18(2-3):179–189. [PubMed]
  • Milburn PB, Brandsma JL, Goldsman CI, Teplitz ED, Heilman EI. Disseminated warts and evolving squamous cell carcinoma in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1988 Aug;19(2 Pt 2):401–405. [PubMed]
  • Maurer TA, Christian KV, Kerschmann RL, Berzin B, Palefsky JM, Payne D, Tyring SK, Berger TG. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol. 1997 May;133(5):577–583. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group